Premature Ejaculation — Causes, Symptoms & Treatment Guide — Symptoms, Causes & Treatment | MyMedicPlus

Premature ejaculation (PE) is the most prevalent male sexual dysfunction, characterised by ejaculation that occurs sooner than desired, with minimal voluntary control, causing personal distress or interpersonal difficulty. The International Society for Sexual Medicine (ISSM) definition of lifelong (primary) PE: ejaculation always or nearly always occurring within approximately 1 minute of vaginal penetration from the first sexual experience, with inability to delay, and associated negative personal consequences (distress, frustration, avoidance). Acquired (secondary) PE develops after a period of normal ejaculatory control. PE affects 20-30% of adult men regardless of age and is widely under-reported and under-treated due to stigma and embarrassment. It is associated with significant psychological distress, reduced sexual confidence, relationship difficulties, and avoidance of sexual intimacy. With appropriate treatment — behavioural, pharmacological, or combined — the majority of men achieve meaningful improvement.

The aetiology of PE is multifactorial. Neurobiological factors: serotonin plays a central role in ejaculatory control — low central serotonin activity reduces the threshold for ejaculatory reflex; genetic polymorphisms in the serotonin transporter gene (5-HTTLPR) are associated with lifelong PE. Penile hypersensitivity to tactile stimulation has been demonstrated in some studies. Psychological and psychosexual factors: performance anxiety (most common acquired PE cause), early sexual experiences associated with rapid ejaculation (conditioned response), relationship conflict, stress and depression, body image concerns, and restrictive sexual attitudes. Medical conditions associated with acquired PE: erectile dysfunction (the most important comorbid condition — fear of losing erection leads to rapid ejaculation); hyperthyroidism; prostatitis (chronic pelvic pain syndrome); urethritis; diabetes. Recreational drug use and alcohol can impair ejaculatory control. Relationship factors: partner communication difficulties, lack of trust, or sexual incompatibility.

The defining symptom is ejaculation occurring sooner than desired — typically within 1-2 minutes of penetration (lifelong PE) or shorter than the patient's own prior normal ejaculatory latency (acquired PE). Intravaginal Ejaculatory Latency Time (IELT) — measured from vaginal penetration to intravaginal ejaculation — is the standard objective measure; PE is generally defined as IELT consistently below 1-2 minutes with associated distress; normal IELT for most men is 5-7 minutes. Clinical assessment: classify as lifelong vs. acquired (lifelong: consistent from first sexual experience; acquired: new deterioration); subjective versus objective (perceived vs. stopwatch-measured IELT); and with or without ED (which must be treated first, as untreated ED commonly causes PE). Psychological impact: performance anxiety, reduced sexual self-confidence, interpersonal tension, avoidance of sexual activity, and relationship dissatisfaction are almost universal.

PE is a clinical diagnosis based on detailed sexual history — no specific investigations are required for straightforward cases. Key history elements: onset and duration of PE (lifelong vs. acquired), IELT estimate (with or without stopwatch measurement — self-reported IELT is a validated measure), severity of distress for both patient and partner, presence of associated erectile dysfunction or other sexual dysfunction, current medications, psychological stressors, and relationship factors. Validated questionnaires: the Index of Premature Ejaculation (IPE) and the Premature Ejaculation Diagnostic Tool (PEDT) standardise assessment and quantify severity. Physical examination: focused genital examination; assess for prostatitis (prostate tenderness on DRE); penile abnormalities. Investigations: thyroid function (TSH) if acquired PE — hyperthyroidism is a treatable cause; urinalysis and MSU if prostatitis suspected; testosterone if low libido comorbid; testicular ultrasound if abnormality detected. Screen for and treat ED before assessing PE treatment response — ED is the most important comorbid condition.

Behavioural therapy: Stop-Start technique (Semans technique) — patient or partner stimulates the penis to the point of near-ejaculation, then stops completely until arousal subsides; repeated multiple times before allowing ejaculation; gradually extends ejaculatory control through learned inhibition. Squeeze technique (Masters and Johnson) — manual pressure applied to the frenulum area at the point of inevitability until arousal subsides; similar efficacy to stop-start. Sensate focus exercises (with couples therapy) — progressively escalating non-demand sexual activities to reduce performance anxiety. Topical anaesthetics (applied 10-20 minutes before intercourse, washed off before penetration): lidocaine 5% cream/gel; lidocaine 9.6%/prilocaine 2.5% metered-dose spray (EMLA or equivalent) — reduces glans sensitivity, prolongs IELT by 4-6 minutes on average. Pharmacotherapy: Dapoxetine (Priligy) — the only specifically licensed on-demand oral treatment for PE; short-acting SSRI, taken 1-3 hours before intercourse (30-60mg); prolongs IELT by 3-fold; used as needed, not daily; fast onset and offset; effective and well tolerated. Off-label daily SSRIs (paroxetine 10-40mg, clomipramine, sertraline 50mg): delayed ejaculation is a well-established side effect harnessed therapeutically; paroxetine most effective (average 8-fold IELT increase); takes 1-2 weeks for effect; must be taken daily. Combination therapy (topical + dapoxetine, or behavioural + pharmacological) is most effective for moderate-severe PE. Treat ED with PDE5 inhibitors first if ED is comorbid — often resolves PE secondary to ED.

Premature ejaculation causes significant psychological, relational, and sexual function complications when persistent and distressing. Psychological impact: shame, embarrassment, and anxiety about sexual performance are near-universal in men with PE — a negative feedback loop develops where anxiety about ejaculating early increases sympathetic arousal, which further shortens IELT and worsens PE; depression is more prevalent in men with PE than in the general population; sexual avoidance behaviours develop when psychological burden becomes significant. Relationship complications: partner dissatisfaction and frustration are common consequences; PE is associated with reduced sexual satisfaction in both partners; relationship conflict and emotional distance follow; female partners of men with PE have higher rates of sexual dysfunction (arousal and orgasm difficulties due to shortened intercourse duration). Erectile dysfunction comorbidity: performance anxiety from PE frequently precipitates secondary erectile dysfunction — anxiety impairs erection acquisition and maintenance; PE and ED commonly coexist and each worsens the other; clinicians must assess for both conditions simultaneously. Fertility impact: in severe lifelong PE (ejaculation at or before penetration), achieving successful intravaginal ejaculation for natural conception may be impossible — assisted reproduction techniques may be required. Medication complications: daily off-label SSRIs used for PE (paroxetine, clomipramine, sertraline) cause nausea, sweating, emotional blunting, weight gain, and discontinuation syndrome; dapoxetine (on-demand) is better tolerated but causes dizziness and nausea in approximately 10–20% of users. Social withdrawal and reduced relationship commitment from fear of sexual intimacy are recognised long-term consequences of untreated and unacknowledged PE.

Open communication with sexual partner reduces performance anxiety — the most important psychosocial factor in acquired PE. Psychosexual therapy or couples therapy addresses relationship dynamics, sexual anxiety, and communication barriers — particularly effective for acquired PE with significant psychological component. Pelvic floor muscle training (Kegel exercises): strengthening pubococcygeus and bulbocavernosus muscles provides voluntary ejaculatory control — RCT evidence supports efficacy in acquired PE. Masturbation before partnered sex (refractory period) reduces arousal level and delays subsequent ejaculation. Manage concomitant anxiety and depression with appropriate therapy and medication — SSRIs for depression also treat PE. Maintain healthy lifestyle: limit alcohol, avoid recreational drugs. Condoms reduce penile sensitivity and may independently help mild PE. Avoid pornography-driven unrealistic expectations about ejaculatory control.

See your GP or a sexual health specialist if premature ejaculation is causing significant personal distress, relationship difficulties, or avoidance of sexual intimacy. PE is a recognised medical condition — not a character failing — and effective treatments are available. Do not suffer in silence or assume nothing can be done. Seek early assessment as PE rarely resolves on its own without specific intervention. See a doctor promptly if PE is a new development (acquired PE), particularly if accompanied by erectile dysfunction, painful ejaculation, urinary symptoms, or pelvic pain — these may indicate an underlying cause (prostatitis, hyperthyroidism, erectile dysfunction) that requires treatment. Both partners benefit from involvement in treatment — couples who attend together have better outcomes.